Is Curis Inc halal to invest in?

According to Musaffa's Shariah screening methodology, Curis Inc (CRIS) is currently classified as HALAL as of March 2026. The classification is based on an evaluation of the company's business activities and financial ratios to determine whether it meets Islamic investment guidelines.

Is Curis Inc a Shariah-compliant stock?

A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Curis Inc using these criteria to determine its compliance status.

Can Muslims buy shares of Curis Inc?

Muslim investors may consider investing in Curis Inc if it meets Shariah compliance standards. Investors typically review the company's business activities, debt levels, and non-permissible income before making a decision.

Why is Curis Inc classified as HALAL?

Musaffa determines the Shariah status of Curis Inc by analyzing whether the company's core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.

How often is the Shariah compliance for Curis Inc updated?

The Shariah compliance status of Curis Inc may be updated periodically when new financial statements, earnings reports, or business activity information become available.

Can a halal stock like Curis Inc become non-compliant?

Yes. A stock that is currently Shariah-compliant may become non-compliant if the company's financial ratios exceed Shariah thresholds or its business activities change.

Where can I check the Shariah status of Curis Inc?

You can check the latest Shariah compliance status of Curis Inc on Musaffa's stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.

CRIS Shariah Compliance

Screening Methodology: AAOIFI

HALAL

Last Updated: March 26, 2026

Report Source: 2025 Annual Report

Curis Inc. Stock Analysis CRIS

United States Health Care Nano Cap Report: 2025 Annual

Curis, Inc. engages in the development and commercialization of drug candidates for the treatment of human cancers. The company is headquartered in Lexington, Massachusetts and currently employs 24 full-time employees. The company went IPO on 2000-08-01. The firm is focused on the development of emavusertib (CA-4948), an orally available, small molecule inhibitor of Interleukin-1 receptor associated kinase (IRAK4). Emavusertib is undergoing testing in the Phase I/II TakeAim Lymphoma study in patients with relapsed/refractory primary central nervous system lymphoma (PCNSL) in combination with the BTK inhibitor ibrutinib, as a monotherapy in the Phase I/II TakeAim Leukemia study in patients with I/II TakeAim Leukemia study in patients with relapsed/refractory acute myeloid leukemia (AML) and relapsed/refractory high risk myelodysplastic syndrome (hrMDS). The Erivedge, is a commercialized orally administered small molecule Hedgehog signaling pathway antagonist. Its other clinical programs include Fimepinostat and CA-170. CA-170 is an oral small molecule drug candidate that targets V-domain Ig Suppressor of T-cell Activation, or VISTA, and PDL1 immune checkpoint proteins.

Key Statistics of Curis Inc (CRIS)

Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.

Today's Range

$0.49$0.51

Today's Open

$0.50

Volume

248.06K

P/E Ratio (TTM)

52 Week Range

$0.49$3.13

Market Cap

22.80M

Avg. Volume

533.97K

Dividend Yield

Financial Metrics & Statements of Curis Inc (CRIS)

FAQ's for Curis Inc (CRIS)

According to Musaffa’s Shariah screening methodology, Curis Inc (CRIS) is currently classified as HALAL as of March 2026. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.